Screener
West Pharmaceutical Services WST Asset write-downs
Asset write-downs at other companies
Other financials
Where this comes from
Reported directly by West Pharmaceutical Services in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000105770-26-000099
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Amortization | 1.1 | 1.5 |
| Stock-based compensation | 17.5 | 8.7 |
| Non-cash restructuring charges | 1.9 | 1.6 |
| Asset impairments | 4.2 | 4.1 |
| Other non-cash items, net | (5.0) | (6.9) |
| Changes in assets and liabilities | (188.9) | (4.0) |
| Net cash provided by operating activities | 213.9 | 306.5 |
| Cash flows from investing activities: |
Item 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is West Pharmaceutical Services's asset write-downs?
- West Pharmaceutical Services (WST) reported asset write-downs of $3.9M in Q2 2026.
- How has West Pharmaceutical Services's asset write-downs changed year-over-year?
- West Pharmaceutical Services's asset write-downs increased by 2.6% year-over-year, from $3.8M to $3.9M.
- What is the long-term trend for West Pharmaceutical Services's asset write-downs?
- Over 4 years (2021 to 2025), West Pharmaceutical Services's asset write-downs has grown at a 20.2% compound annual growth rate (CAGR), from $5.6M to $11.7M.
Ask your AI about West Pharmaceutical Services's asset write-downs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude